Status:

COMPLETED

Personalized Auricular Vagus Nerve Stimulation in Intractable Chronic Low Back Pain

Lead Sponsor:

Aurimod GmbH

Collaborating Sponsors:

Klinikum Klagenfurt am Wörthersee

La Tour Hospital

Conditions:

Chronic Low-back Pain

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

One in five people in the general adult population suffer from chronic pain, a figure that is higher than heart disease, cancer, and diabetes combined. A majority of these patients is suffering from c...

Eligibility Criteria

Inclusion

  • Male or female aged 18 to 65 years at screening
  • Patient has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures
  • Chronic back pain with or without leg pain (CBLP) persisting for at least 3 months
  • A minimum of 70 (out of 180) points on the Computer User Self-Efficacy Scale at the screening visit
  • Patient is constant with respect to pain treatment during the screening phase
  • A daily average VAS \>= 4 on at least half of the days in the screening phase
  • Compliance with the daily status reporting requirements as demonstrated by having valid required data entries for all days. It is acceptable if data of one day is missing in the screening phase

Exclusion

  • Patients with age under 18
  • Hemophilia
  • Infection, eczema, or psoriasis at application site
  • Numbed and desensitized skin at the application site
  • Florid malignant diseases
  • Mental and physical impairments that represent a source of risk for handling the device
  • The presence of a cardiac pacemaker, defibrillator, cochlear implant, or other active implantable device
  • Vagal hypersensitivity
  • Indication for back surgery
  • High-grade spinal stenosis
  • Patients with other active implants
  • Patients with autonomic disorders
  • Patients with diabetes type I or II
  • Patients taking Beta-Blockers
  • Patients taking drugs carrying the potential risk of arrhythmia (tricyclic medications, Alzheimer drugs, etc.)
  • Clinically significant hip or knee arthritis
  • Allergy against rescue medication used during the study
  • History of Vagus Nerve Stimulation
  • Pregnant or nursing female patients
  • Patients with arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies detected during ECG at screening

Key Trial Info

Start Date :

April 13 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 25 2022

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT04753528

Start Date

April 13 2021

End Date

October 25 2022

Last Update

February 1 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Klinikum Klagenfurt am Wörthersee

Klagenfurt, Carinthia, Austria, 9020

2

Hopital de La Tour

Geneva, Switzerland, 1217